Kintara Therapeutics, Inc. , a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients.
Kintara Therapeutics stock last closed at $3.68, up 2.79% from the previous day, and has decreased 81.27% in one year. It has underperformed other stocks in the Biotechnology industry by 0.54 percentage points. Kintara Therapeutics stock is currently +31.43% from its 52-week low of $2.80, and -91.24% from its 52-week high of $42.00.
As of Mar 24, 2023, there are 1.68M KTRA shares outstanding. The market cap of KTRA is $6.17M. In the last 24 hours, 2168 KTRA shares were traded.
You need a brokerage account in order to access the NASDAQ market and buy KTRA shares.
In our opinion, eToro is the best brokerage. eToro gives you:
Get $10 towards your stock purchase by creating an account with eToro today.Open eToro Account
Now that you've chosen your brokerage, it's time to fill out some personal details so you are able to buy KTRA stock today.
Now that you've created your account on stock market app, you need to deposit funds:
Check out the walkthrough below for more details transferring money into your new investment account.
Once you have selected the best place to buy Kintara Therapeutics stock, it's important to analyze their stock before you invest, so you truly understand the risk as well as the opportunity.
WallStreetZen was built to help part-time investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on KTRA's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge KTRA's intrinsic value.
Using relative valuations methods:
You can do more valuation analysis on KTRA's stock here.
Out of 1 Wall Street analysts who track KTRA, the consensus analyst rating on KTRA is a Hold
Please note that analyst forecasts are not recommendations, nor are they financial advice.
Jason McCarthy, a bottom 2% analyst from Maxim Group downgrades KTRA to a hold rating, on Sep 29, 2022.
You can dive deeper into what analysts are saying on the Kintara Therapeutics stock forecast page.
Over the past year, insiders at KTRA have not bought or sold any shares.
Dig into more about who owns KTRA shares here.
No, Kintara Therapeutics doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
You have two primary types of orders:
Press the Open Trade button and eToro will execute the order.
If you need more help investing in stocks on eToro, watch the how to video below:
Now that you own some KTRA shares, you'll want to stay up-to-date on your new stock purchase.
Make a watchlist to get the latest updates about your KTRA stock.
To reiterate, here are the 6 steps to buy Kintara Therapeutics stock:
If you are looking for a brokerage account, eToro is our favorite venue.Get Started with eToro Today
If you would like to watch your new investment in Kintara Therapeutics, click below.
How much does it cost to buy one Kintara Therapeutics share?
Is now a good time to buy Kintara Therapeutics stock?
What is the best way to buy Kintara Therapeutics stock?